Co-Authors
This is a "connection" page, showing publications co-authored by YU SHEN and ARLENE ODELIA SIEFKER-RADTKE.
Connection Strength
0.948
-
Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. J Urol. 2013 Dec; 190(6):2019.
Score: 0.459
-
A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 01; 119(3):540-7.
Score: 0.107
-
Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013 Aug; 64(2):307-13.
Score: 0.104
-
p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One. 2012; 7(1):e30206.
Score: 0.102
-
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004 Aug; 172(2):481-4.
Score: 0.061
-
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol. 2004 Jan; 171(1):145-8.
Score: 0.059
-
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol. 2003 Apr; 169(4):1295-8.
Score: 0.056